U.S. markets close in 3 hours 43 minutes

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.1300-0.0300 (-2.59%)
As of 12:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close1.1600
Open1.1500
Bid1.1200 x 3000
Ask1.1300 x 21500
Day's Range1.1200 - 1.1583
52 Week Range1.1200 - 5.3300
Volume445,786
Avg. Volume1,183,329
Market Cap121.03M
Beta (5Y Monthly)1.37
PE Ratio (TTM)3.06
EPS (TTM)0.3690
Earnings DateOct 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
226% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Lexicon Pharmaceuticals (LXRX) Q3 Earnings Beat Estimates
    Zacks

    Lexicon Pharmaceuticals (LXRX) Q3 Earnings Beat Estimates

    Lexicon (LXRX) delivered earnings and revenue surprises of 57.78% and -94.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Lexicon Pharmaceuticals: Q3 Earnings Insights

    Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) rose 5.7% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share decreased 330.00% year over year to ($0.43), which missed the estimate of $0.26.Revenue of $6,634,000 decreased by 97.75% from the same period last year, which missed the estimate of $16,870,000.Outlook Earnings guidance hasn't been issued by the company for now.View more earnings on LXRXRevenue guidance hasn't been issued by the company for now.Recent Stock Performance 52-week high: $5.3352-week low: $1.22Price action over last quarter: down 33.51%Company Description Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates. Its drugs candidates include XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy; Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes; sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease; and LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Wednesday's After-Market Session * Stocks That Hit 52-Week Lows On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACCESSWIRE

    Lexicon Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Lexicon Pharmaceuticals, Inc.